SLC5A2 and Cirrhosis: In this large, multi-institutional cohort study of 120 health care organizations that included over 118 000 patients, the use of SGLT-2 inhibitors in patients with cirrhosis taking furosemide and spironolactone was associated with significantly lower rates of our composite outcome of serious liver events compared with patients with cirrhosis who did not receive SGLT-2 inhibitors.